Passage BIO PASG 深 滬
交易中 11-04 11:13:42 美东时间
3.55
+0.150
+4.41%
華盛通- 最 高3.55
- 今 開3.48
- 成交量 1.50万股
- 最 低 3.45
- 昨 收 3.40
- 總市值 1142.32万
- 52周最高 20.00
- 市盈率 靜 --
- 換手率 0.47%
- 52周最低 3.29
- 委 比 -50.46%
- 總股本 321.78万
- 歷史最高 764.60
- 量 比 8.24
- 振 幅 2.94%
- 歷史最低 3.29
- 每 手 1
- 風險率 3.14%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Passage Bio收跌3.77%，成交额3.87万美元
11月3日，Passage Bio（PASG）收跌3.77%，报3.32美元，成交额3.87万美元，市值1068.27万美元。 行情数据 • 开盘价：3.45美...
11-03 08:57
Passage Bio收跌0.33%，成交额5492美元
10月27日，Passage Bio（PASG）收跌0.33%，报3.36美元，成交额5492美元，市值1080.8万美元。 行情数据 • 开盘价：3.37美元...
10-27 07:58
Passage Bio收跌2.78%，成交额5.98万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 08:02
Passage Bio Q2 EPS $(2.44) Beats $(3.47) Estimate
Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(3.47) by 29.68 percent. This is a 17.57 percent increase over losses of $(2.96) per share from the same period last year.
08-10 19:45
美股夜盘 | 中驰车福涨95.61%，Eco Wave Power Global AB Sponsored ADR涨29.71%
Elme Communities涨-26.24%；宝视来涨-18.24%；Passage BIO涨-17.52%
06-25 08:05
9 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-market session. The market value of their outstanding shares is at $9.7 million. Greenland Mines (NASDAQ:GRML) stock moved upwards by 7.18% to $0.24. The company's market cap stands at $34.7 million. Lunai...
06-25 05:05
Passage Bio, Remix Therapeutics Sign All-Stock Business Combination Agreement; Combined Entity To Operate Under Remix Therapeutics, RMTX Ticker On Nasdaq
Passage Bio, Inc. (Nasdaq: PASG) ("Passage Bio") and Remix Therapeutics, Inc. ("Remix"), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that they have entered into a definitive merge...
06-25 04:07
Passage Bio and Remix Therapeutics Announce Merger Agreement
Passage Bio and Remix Therapeutics have agreed to merge in an all-stock transaction, with the combined company operating as Remix Therapeutics. The merger is supported by a $100 million private placement financing, which will fund operations into 2028. Remix’s lead program, REM-422, an mRNA degrader targeting MYB, is in Phase 1/2 trials for cancers like ACC and AML. The transaction is expected to close in Q4 2026, with the combined company led by...
06-24 20:05
Passage Bio Ends Key Collaborations and Office Lease
Passage Bio ( ($PASG) ) has provided an announcement. On May 21, 2026, Passage ...
05-28 05:31
